Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 8Sarcoma, Endometrial Stromal 1Recurrence 1Perivascular Epithelioid Cell Neoplasms 1Neoplasms by Site 1Neoplasms 1Endometrial Neoplasms 1ER+ Breast Cancer 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Diseases 1Brain Neoplasms 1Brain Diseases 1Advanced Breast Cancer 1Adenosarcoma of the uterus 1

Interventions

exemestane 2Letrozole 2ribociclib 1elacestrant 1Taxes 1Tamoxifen 1Radiosurgery 1Psychiatric Rehabilitation 1Neoadjuvant Therapy 1Mental Status and Dementia Tests 1Leuprolide 1Immunotherapy 1Goserelin 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × elacestrant × 30 days × Clear all
NCT06492616 2026-05-27

ELEGANT

Stemline Therapeutics, Inc.

Phase 3 Recruiting
4,220 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡